肾衰宁胶囊辅助治疗慢性肾功能衰竭的疗效观察

冯跃华　王霄一

[摘要] 目的 探讨肾衰宁胶囊辅助治疗慢性肾功能衰竭的有效性及安全性。 方法 选择2017年2月至2019年10月本院接受治疗的慢性肾功能衰竭患者80例为研究对象，按照随机数字表法分为观察组与对照组，每组各40例。两组患者均接受常规治疗，对照组给予缬沙坦治疗，观察组在对照组基础上给予肾衰宁胶囊辅助治疗。比较两组临床治疗有效率与不良反应发生情况，同时观察两组治疗前后肾功能指标[血肌酐（Scr）、尿素氮（BUN）、尿白蛋白排泄率（UAER）]水平。 結果 治疗4个月后，观察组患者临床治疗有效率为92.50%，高于对照组的65.00%，差异有统计学意义（χ2=9.038，P<0.05）;治疗前，观察组患者Scr、BUN、UAER水平与对照组比较，差异无统计学意义（P>0.05）;治疗后，观察组患者Scr、BUN水平低于对照组，差异有统计学意义（P<0.05）;观察组患者不良反应总发生率为7.50%，低于对照组的20.00%，但组间比较，差异无统计学意义（χ2=2.635，P>0.05）。 结论 肾衰宁胶囊用于辅助治疗慢性肾功能衰竭，疗效显著且安全。

[关键词] 慢性肾功能衰竭;肾衰宁;肾功能;血肌酐

[中图分类号] R692.5          [文献标识码] B          [文章编号] 1673-9701（2021）20-0109-03

Observation of the efficacy of Shenshuaining capsule in adjuvant treatment of chronic renal failure

FENG Yuehua   WANG Xiaoyi

Department of Nephrology， the First People′s Hospital of Huzhou in Zhejiang Province， Huzhou   313000， China

[Abstract] Objective To explore the efficacy of Shenshuaining capsule in adjuvant treatment of chronic renal failure （CRF）. Methods From February 2017 to October 2019， a total of 80 patients with CRF treated in our hospital were selected as the subjects of research and were divided into the observation group and the control group according to random number table method， with 40 patients in each group. Both groups of patients received conventional treatment，the control group was treated with valsartan， and the observation group was administered Shenshuaining capsule as adjuvant treatment on the basis of the control group. The effective rate of clinical treatment and the occurrence of adverse reactions （ADRs） were compared between the observation group and the control group， and the levels of renal function indexes [serum creatinine （Scr）， blood urea nitrogen （BUN） and urinary albumin excretion rate （UAER）] in the two groups before and after treatment were observed. Results After 4 m of treatment， the effective rate of clinical treatment in the patients of the observation group was 92.50%， higher than the 65.00% in the patients of the control group， and the difference was statistically significant（χ2=9.038， P<0.05）. Before treatment，when comparisons were made between the patients of the observation group and the patients of the control group in terms of the levels of Scr， BUN and UAER， the differences were statistically insignificant（P>0.05）; after treatment， the levels of Scr and BUN in the patients of the observation group were lower than those in the patients of the control group， and the differences were statistically significant（P<0.05）;the total incidence of ADRs in the patients of the observation group was 7.50%， lower than the 20.00% in the patients of the control group， but the difference between the two groups was statistically insignificant（χ2=2.635， P>0.05）. Conclusion In adjuvant treatment of the patients with CRF， Shenshuaining can effectively improve the effective rate of clinical treatment and improve the renal function of the patients， and it has a certain safety.